China NT Pharma Group Past Earnings Performance
Past criteria checks 0/6
China NT Pharma Group has been growing earnings at an average annual rate of 49.2%, while the Pharmaceuticals industry saw earnings growing at 5.9% annually. Revenues have been declining at an average rate of 25.4% per year.
Key information
49.2%
Earnings growth rate
53.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.6% |
| Revenue growth rate | -25.4% |
| Return on equity | n/a |
| Net Margin | -454.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
A Look At The Intrinsic Value Of China NT Pharma Group Company Limited (HKG:1011)
Mar 06
China NT Pharma Group Company Limited's (HKG:1011) Price Is Right But Growth Is Lacking
Dec 29Estimating The Intrinsic Value Of China NT Pharma Group Company Limited (HKG:1011)
Oct 30Is China NT Pharma Group (HKG:1011) Using Too Much Debt?
Apr 13Revenue & Expenses Breakdown
How China NT Pharma Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 7 | -33 | 64 | 0 |
| 30 Jun 23 | 169 | -44 | 67 | 0 |
| 31 Mar 23 | 188 | -55 | 87 | 0 |
| 31 Dec 22 | 0 | -50 | 27 | 0 |
| 30 Sep 22 | 222 | -121 | 166 | 0 |
| 30 Jun 22 | 236 | -175 | 225 | 0 |
| 31 Mar 22 | 231 | -162 | 232 | 0 |
| 31 Dec 21 | 227 | -150 | 239 | 0 |
| 30 Sep 21 | 235 | -147 | 231 | 0 |
| 30 Jun 21 | 244 | -145 | 224 | 0 |
| 31 Mar 21 | 233 | -167 | 221 | 0 |
| 31 Dec 20 | 222 | -189 | 218 | 0 |
| 30 Sep 20 | 185 | -271 | 251 | 0 |
| 30 Jun 20 | 149 | -353 | 283 | 0 |
| 31 Mar 20 | 151 | -351 | 281 | 0 |
| 31 Dec 19 | 153 | -350 | 279 | 0 |
| 30 Sep 19 | 254 | -547 | 391 | 0 |
| 30 Jun 19 | 354 | -744 | 502 | 0 |
| 31 Mar 19 | 463 | -670 | 514 | 0 |
| 31 Dec 18 | 572 | -596 | 525 | 0 |
| 30 Sep 18 | 587 | -190 | 390 | 0 |
| 30 Jun 18 | 602 | 216 | 256 | 0 |
| 31 Mar 18 | 604 | 215 | 253 | 0 |
| 31 Dec 17 | 605 | 214 | 251 | 0 |
| 30 Jun 17 | 288 | 78 | 186 | 0 |
| 31 Mar 17 | 324 | 52 | 189 | 0 |
| 31 Dec 16 | 360 | 25 | 192 | 0 |
| 30 Sep 16 | 884 | 109 | 314 | 0 |
| 30 Jun 16 | 853 | 101 | 324 | 0 |
| 31 Mar 16 | 850 | 94 | 332 | 0 |
| 31 Dec 15 | 848 | 88 | 341 | 0 |
| 30 Sep 15 | 843 | 62 | 312 | 0 |
| 30 Jun 15 | 837 | 36 | 284 | 0 |
| 31 Mar 15 | 851 | 19 | 300 | 0 |
| 31 Dec 14 | 865 | 2 | 317 | 0 |
| 30 Sep 14 | 750 | -118 | 325 | 0 |
| 30 Jun 14 | 636 | -239 | 334 | 0 |
| 31 Mar 14 | 695 | -456 | 400 | 0 |
| 31 Dec 13 | 754 | -673 | 467 | 0 |
| 30 Sep 13 | 759 | -1,077 | 594 | 0 |
Quality Earnings: 1011 is currently unprofitable.
Growing Profit Margin: 1011 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1011 is unprofitable, but has reduced losses over the past 5 years at a rate of 49.2% per year.
Accelerating Growth: Unable to compare 1011's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1011 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (0.1%).
Return on Equity
High ROE: 1011's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.